Antibody pharmacokinetics and pharmacodynamics.

By E. Lobo, R. Hansen, J. Balthasar. Journal of Pharmacy and Science, 2004

908 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Therapeutic antibodies for autoimmunity and inflammation (2010, background): “The terminal half-life for chimeric, humanized and human antibody drugs in the circulation varies widely (∼3–27 days”
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “Although the amino acid sequences of the Fc regions are identical, the markedly shorter plasma half-life of etanercept versus IgG1 mAbs or other Fc fusion proteins (Table 1; Lobo et al., 2004) suggests that the conformation or steric accessibility of the Fc region of etanercept may be different from”
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies (2010, background): “Immune responses influence the distribution of the antibody throughout the body and the elimination rates of administered antibodies.([11,12]) Although in recent years, especially, humanized and fully human mAbs have been developed, these mAbs can also provoke immunogenic reactions.”
Potent antibody therapeutics by design (2006, background): “Antibody immunogenicity is also influenced by clinical parameters, including the dose, route and frequency of administration, as well as patient-specific factors, such as disease and immune status, MHC haplotype and concomitant medicatio”